Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Metastatic breast cancers (MBC) previously treated with anthracyclines (A) and taxanes (T) have a complicated management. Gemcitabine (G)–cisplatin (C) combinations have been used as synergistic salvage therapy in MBC and are considered as another option for patients with important symptoms and aggressive visceral disease. We analyzed the safety and efficacy of GC in AT-pretreated MBC, as well as overall survival (OS) and time to progression (TTP). Forty-nine subjects received IV G 750 mg/m2 and C 30 mg/m2, both d1 and d8 every 3 weeks. Response evaluation was performed every second cycle and in the end of treatment. GC protocol was the first-line palliative chemotherapy in half of the cases, and median number of cycles/patient were 4(2–12). Lung (75.5%) was the most frequent site of metastasis. Most of the patients related clinical improvement with chemotherapy with minimal/mild tolerable collateral effects in 85.7% of cases. Following 34 months, mean OS/TTP was 13.12/6.6 months. Objective-responded patients (40.3%) were statistically associated with the improvement in symptoms after CT (P < 0.01), and OS was directly correlated with chemotherapy response (P < 0.01). HER-2 overexpression was a prognostic factor with reduced OS (P = 0.01). GC protocol was effective and tolerable in objective-responded patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2008;108:319–31.

    Article  PubMed  CAS  Google Scholar 

  2. Greenberg PA, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.

    PubMed  CAS  Google Scholar 

  3. Chan D, et al. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Invest New Drugs. 2010;28(6):859–65.

    Article  PubMed  CAS  Google Scholar 

  4. Kim HJ, et al. Gemcitabine and vinorelbine combination chemotherapy in anthracycline and taxane pretreated advanced breast cancer. Can Res Treat. 2008;40(2):81–6.

    Article  Google Scholar 

  5. Seo JH, et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol. 2007;59:269–74.

    Article  PubMed  CAS  Google Scholar 

  6. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245–9.

    PubMed  CAS  Google Scholar 

  7. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer. 2002;1(Suppl 3):24–9.

    Article  Google Scholar 

  8. Bergman AM, Ruiz van Haperen VW, Veerman G. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521–30.

    PubMed  CAS  Google Scholar 

  9. Peters GJ, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22:72–9.

    PubMed  CAS  Google Scholar 

  10. Yang LY, Li L, Jiang H, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumour cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000;6:773–81.

    PubMed  CAS  Google Scholar 

  11. Pegram MD, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–71.

    PubMed  CAS  Google Scholar 

  12. Mohran TZ. Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst. 2004;16:8–14.

    PubMed  Google Scholar 

  13. Stemmler J, Wohlrab B, Bosse D. Gemcitabine plus cisplatin in intensively pretreated metastatic breast cancer: a phase II trial (Abstract). Proc Am Soc Clin Oncol. 2003;22 (abstr 291).

  14. Galvez CA, Calmarini F, Curie M. Monthly cisplatin (C) and gemcitabine (G) as second-line chemotherapy for patients with advanced breast cancer (Abstract). Breast Cancer Res Treat. 2000;64(1):81.

    Google Scholar 

  15. Burch PA, Maillard J, Hillman D. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy, a North Central Cancer Treatment Group study (Abstract). Breast Cancer Res Treat. 2000;64:81.

    Google Scholar 

  16. Chaudhry S, Abel-Ralman HA, Patil R. Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (MBC) Proc Am Soc Clin Oncol. 2000;19 (abst 430).

  17. Tas F, et al. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane pretreated metastatic breast cancer. Invest New Drugs. 2008;26(4):363–8.

    Article  PubMed  CAS  Google Scholar 

  18. Heinemann V, et al. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:640–6.

    Article  PubMed  CAS  Google Scholar 

  19. Sanchez-Escribano MR, Alés-Martinez JE, Aramburo-González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol. 2007;9(7):459–64.

    Article  Google Scholar 

  20. Fuentes H, et al. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs. 2006;17(5):565–70.

    Article  PubMed  CAS  Google Scholar 

  21. Chew HK, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27:2163–9.

    Article  PubMed  CAS  Google Scholar 

  22. Somali I, et al. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy. 2009;55(3):155–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, School of Medicine of Ribeirão Preto, São Paulo University, Avenida Bandeirantes, 3900, 8th Floor, Ribeirão Preto, SP, 14048-900, Brazil

    Luiz Gustavo Oliveira Brito, Jurandyr Moreira de Andrade, Heitor Ricardo Cosiski Marana & Daniel Guimarães Tiezzi

  2. Department of Internal Medicine, School of Medicine of Ribeirão Preto, São Paulo University, Ribeirão Preto, Brazil

    Thiago Lins-Almeida, Fábio Eduardo Zola, Mariana Novaes Pinheiro & Fernanda Maris Peria

Authors
  1. Luiz Gustavo Oliveira Brito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jurandyr Moreira de Andrade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thiago Lins-Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fábio Eduardo Zola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariana Novaes Pinheiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heitor Ricardo Cosiski Marana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel Guimarães Tiezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fernanda Maris Peria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luiz Gustavo Oliveira Brito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brito, L.G.O., de Andrade, J.M., Lins-Almeida, T. et al. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Med Oncol 29, 33–38 (2012). https://doi.org/10.1007/s12032-010-9793-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9793-8

Keywords

Search

Navigation